Hepatocarcinoma in viral and metabolic liver disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 46, Issue 4, 2008, Pages 370-375

  Rosenthal, Philip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ablation; Hepatocellular carcinoma; Liver transplantation; Metabolic liver disease; Pathogenesis; Screening; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; SORAFENIB;

CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHEMOEMBOLIZATION; CHROMOSOMAL INSTABILITY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER SURGERY; LIVER TRANSPLANTATION; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROTON THERAPY; REVIEW; SEROCONVERSION; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS;

CARCINOMA, HEPATOCELLULAR; CHILD; CHRONIC DISEASE; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PREVALENCE; RISK FACTORS; SENTINEL SURVEILLANCE; VIRAL HEPATITIS VACCINES;

EID: 41449093701     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318158799b     Document Type: Review

References (75)

1. American Cancer Society. Cancer Facts and Figures. Atlanta: American Cancer Society; 2007.
2. Gish RG. Risk factors and treatment for hepatocellular carcinoma. Gastroenterol Hepatol 2006;2:477-8.
3. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liv Dis 1999;19:271-85.
4. Stocker JT. Hepatic tumors. In: Balistreri WF, Stocker JT (eds). Pediatric Hepatology. New York: Hemisphere; 1990.pp. 399-488.
5. Darbari A, Sabin KM, Shapiro CN, et al. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003;38:560-6.
6. Stiller CA, Pritchard J, Steliarova-Foucher E. Liver cancer in European children: incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2115-23.
7. Wen W-H, Chang M-H, Hsu H-Y, et al. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr 2004;144:397-9.
8. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006;43:556-62.
9. Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999;94:2224-9.
10. Zhou H, Fischer HP. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol 1998;22:742-8.
11. McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006;66:743-50.
12. Baumann U, Duhme V, Auth MK, et al. Lectin-reactive alphafetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma. J Pediatr Gastroenterol Nutr 2006;43:77-82.
13. Kumari TP, Shanvas A, Mathews A, et al. Hepatocellular carcinoma: a rare late event in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2000;22:289-90.
14. Bhadri VA, Stormon MO, Arbuckle S, et al. Hepatocellular carcinoma in children with Alagille syndrome. J Pediatr Gastroenterol Nutr 2005;41:676-8.
15. Weinstein S, Scottolini AG, Loo SY, et al. Ataxia telangiectasia with hepatocellular carcinoma in a 15-year-old girl and studies of her kindred. Arch Pathol Lab Med 1985;109:1000-4.
16. Brunati A, Feruzi Z, Sokal E, et al. Early occurrence of hepatocellular carcinoma in biliary atresia treated by liver transplantation. Pediatr Transplant 2007;11:117-9.
17. Bauman ME, Pound DC, Ulbright TM. Hepatocellular carcinoma arising in congenital hepatic fibrosis. Am J Gastroenterol 1994;89:450-1.
18. Cetta F, Mazzarella L, Bon G, et al. Genetic alterations in hepatoblastoma and hepatocellular carcinoma associated with familial adenomatous polyposis. Med Pediatr Oncol 2003;41:496-7.
19. Abbondanzo SL, Manz HJ, Klappenbach RS, et al. Hepatocellular carcinoma in an 11-year-old girl with Fanconi's anemia. Report of a case and review of the literature. Am J Pediatr Hematol Oncol 1986;8:334-7.
20. Sasaki M, Hodo Y, Nakanuma Y. Hepatocellular carcinoma arising in primary biliary cirrhosis presenting with nodular regenerative hyperplasia: report of an autopsy case. J Gastroenterol Hepatol 2006;21:1866-8.
21. Otto G, Herfarth C, Senninger N, et al. Hepatic transplantation in galactosemia. Transplantation 1989;47:902-3.
22. Gruner BA, DeNapoli TS, Andrews W, et al. Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol 1998;20:274-8.
23. Burri E, Steuerwald M, Cathomas G, et al. Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol 2006;18:437-41.
24. Vileisis RA, Sorensen K, Gonzalez-Crussi F, et al. Liver malignancy after parenteral nutrition. J Pediatr 1982;100:88-90.
25. Knisely A, Strautnieks SS, Meier Y, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006;44:478-86.
26. Scheers I, Bachy V, Stephenne X, et al. Risk of hepatocellular carcinoma in liver mitochondrial respiratory chain disorders. J Pediatr 2005;146:414-7.
27. Kanai Y, Tsuda H, Oda T, et al. Analysis of the neurofibromatosis 2 gene in human breast and hepatocellular carcinomas. Jpn J Clin Oncol 1995;25:1-4.
28. Giannitrapani L, Soresi M, La Spada E, et al. Sex hormones and risk of liver tumor. Ann NY Acad Sci 2006;1089:228-36.
29. Gensini GF, Conti AA. Association between hepatocellular carcinoma and polycythemia vera. Recenti Prog Med 2002;93:25-7.
30. Franco LM, Krishnamurthy V, Bali D, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 2005;28:153-62.
31. Demo E, Frush D, Gottfried M, et al. Glycogen storage disease type III - hepatocellular carcinoma a long-term complication? J Hepatol 2007;46:492-8.
32. Jain D, Hui P, McNamara J, et al. Bloom syndrome in sibs: first reports of hepatocellular carcinoma and Wilms tumor with documented anaplasia and nephrogenic rests. Pediatr Dev Pathol 2001;4:585-9.
33. Savas N, Canan O, Ozcay F, et al. Hepatocellular carcinoma in Wilson's disease: a rare association in childhood. Pediatr Transplant 2006;10:639-43.
34. Mehdi A, Marteau P, Lavergne A, et al. Hepatocellular carcinoma in a patient with psoriasis and methotrexate-induced cirrhosis. Gastroenterol Clin Biol 1991;15:464-5.
35. Yu S-B, Kim H-Y, Eo H, et al. Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. World J Surg 2006;30:43-50.
36. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology Group. J Clin Oncol 2002;20:2798-804.
37. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.
38. Miura N, Horikawa I, Nishimoto A, et al. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet 1997;93:56-62.
39. Urabe Y, Nouso K, Higashi T, et al. Telomere length in human liver diseases. Liver 1996;16:293-7.
40. Kitada T, Seki S, Kawakita N, et al. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun 1995;211:33-9.
41. Plentz RR, Schlegelberger B, Flemming P, et al. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. Hepatology 2005;42:522-6.
42. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002;16:935-42.
43. Plentz RR, Caselitz M, Bleck JS, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 2004;40:80-6.
44. Farazi PA, Glickman J, Horner J, et al. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 2006;66:4766-73.
45. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-38.
46. Ueda H, Ullrich SJ, Gangemi JD, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;9:41-7.
47. Majumder M, Ghosh AK, Steele R, et al. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001;75:1401-7.
48. Nose H, Imazeki F, Ohto M, et al. p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer 1993;72:355-60.
49. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8.
50. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature 1991;350:429-31.
51. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338:1356-9.
52. Marrogi AJ, Khan MA, van Gijssel HE, et al. Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma. J Natl Cancer Inst 2001;93:1652-5.
53. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006;25:3787-800.
54. El-Bassiouni A, Nosseir M, Zoheiry M, et al. Immunohistochemical expression of CD95 (Fas), c-myc, and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease, and hepatocellular carcinoma. APMIS 2006;114:420-7.
55. Romano PR, McCallus DE, Pachuk CJ. RNA interference-mediated prevention and therapy for hepatocellular carcinoma. Oncogene 2006;25:3857-65.
56. Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006;209:549-58.
57. Rudnick DA, Liao Y, An J-K, et al. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Hepatology 2004;39:1048-55.
58. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic disease. Hepatology 2005;42:514-21.
59. McMahon BJ, London T. Workshop on screening for hepatocellular carcinoma. J Natl Cancer Inst 1991;83:916-9.
60. Colombo M. Hepatocellular carcinoma. J Hepatol 1992;15:225-36.
61. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003;39:1076-84.
62. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27:273-8.
63. Saab S, Ly D, Nieto J, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003;9:672-81.
64. Arguedas MR, Chen VK, Eloubeidi MA, et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003;98:679-90.
65. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32:842-6.
66. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidencebased management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47.
67. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24.
68. Bruix J, Sherman M. Management of hepatocellular carcinoma. Practice guidelines committee, American Association for the Study of Liver Disease. Hepatology 2005;42:1208-36.
69. Czauderna P. Adult type vs. childhood hepatocellular carcinoma - are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol 2002;39:519-23.
70. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
71. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
72. Yeo W, Mo KF, Chan SL, et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007;45:1382-9.
73. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831-42.
74. Onaca N, Davis GL, Goldstein RM, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the international registry of hepatic tumors in liver transplantation. Liver Transpl 2007;13:391-9.
75. Chang M-H, Shau W-Y, Chen C-J, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000;284:3040-2.